This study highlighted the significant benefits of Trastuzumab Deruxtecan in improving progression-free and overall survival in HER2-low expression breast cancer patients, drawing attention to ADC drugs as a promising area of research. The gene discussed is ERBB2; the disease is breast carcinoma.